Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Acelyrin (SLRN) News Today

Acelyrin logo

SLRN Latest News

Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
Acelyrin: Potential Buyout Led By Concentra Biosciences
Acelyrin Stock Jumps on Concentra Acquisition Interest
Acelyrin Stock Jumps on Concentra Acquisition Interest
Alumis price target lowered to $26 from $32 at Oppenheimer
Piper Sandler Sticks to Their Buy Rating for ACELYRIN, INC. (SLRN)
ACELYRIN, INC. (SLRN) Receives a Buy from Wells Fargo
Acelyrin Inc trading halted, news pending
Alumis and ACELYRIN Agree to Merge in All-Stock Deal
Alumis, Acelyrin to merge in all-stock transaction
ACELYRIN, INC. (SLRN) Receives a Buy from TD Cowen
Acelyrin price target lowered to $3 from $6 at Citi
What's Going On With ACELYRIN Shares Friday?
Get Acelyrin News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SLRN Media Mentions By Week

SLRN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SLRN
News Sentiment

0.00

0.60

Average
Medical
News Sentiment

SLRN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SLRN Articles
This Week

0

0

SLRN Articles
Average Week

Get the Latest News and Ratings for SLRN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Acelyrin and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NASDAQ:SLRN) was last updated on 5/15/2026 by MarketBeat.com Staff.
From Our Partners